![Tina Flatau](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Tina Flatau is currently a Director at Sixfold Bioscience, Inc. She previously worked as the Managing Director at MedAnnex Ltd. and as the Vice President-Alliances & Project Management at Prosensa Holding NV.
| Companies | Position | Start |
|---|---|---|
Sixfold Bioscience, Inc.
 Sixfold Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which develops next-generation in vivo delivery systems for RNA therapeutics | Director/Board Member | - |
| Companies | Position | End |
|---|---|---|
MedAnnex Ltd.
 MedAnnex Ltd. Miscellaneous Commercial ServicesCommercial Services Develops biotechnology approaches for treating autoimmune diseases | Chief Executive Officer | 01/03/2019 |
| PROSENSA HOLDING NV | Corporate Officer/Principal | - |
Active
Inactive
Listed companies
Private companies
| Private companies | 3 |
|---|---|
Prosensa Holding NV
 Prosensa Holding NV BiotechnologyHealth Technology Engages in the development of ribonucleic acid-modulating or RNA-modulating, therapeutics for the treatment of genetic disorders | Health Technology |
MedAnnex Ltd.
MedAnnex Ltd. Miscellaneous Commercial ServicesCommercial Services Develops biotechnology approaches for treating autoimmune diseases | Commercial Services |
Sixfold Bioscience, Inc.
Sixfold Bioscience, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which develops next-generation in vivo delivery systems for RNA therapeutics | Commercial Services |
Select your edition
All financial news and data tailored to specific country editions
